Longer use of tamoxifen shown to cut risk of breast cancer recurrence

By Deena Beasley CHICAGO (Reuters) – Breast cancer is less likely to recur if women previously treated for the disease take the drug tamoxifen for 10 years, instead of the recommended five years, according to a British study. The study was a component of a larger international trial, for which similar results were announced last year. “I think it’s huge because it’s the second trial to show a benefit for 10 years versus five years,” said Dr. Sandra Swain, medical director of the Cancer Institute at Washington Hospital Center and president of the American Society of Clinical Oncology, or ASCO. …